You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 4,999,291

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,999,291

Title:	Production of human pluripotent granulocyte colony-stimulating factor
Abstract:	Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
Inventor(s):	Lawrence M. Souza
Assignee:	Amgen Inc
Application Number:	US07/319,919
Patent Claims:	1. A purified and isolated DNA sequence consisting essentially of a DNA sequence encoding human pluripotent granulocyte colony-stimulating factor. 2. A purified and isolated DNA sequence according to claim 1 wherein said DNA sequence is a cDNA sequence. 3. A plasmid or viral DNA vector comprising a DNA sequence according to claim 1. 4. A procaryotic or eucaryotic host cell stably transformed or transfected with a DNA sequence according to claim 1 in a manner allowing expression of pluripotent colony-stimulating factor. 5. A process for the production of a polypeptide product, said process comprising: growing under suitable nutrient conditions, procaryotic or eucaryotic host cells transformed or transfected with a DNA sequence encoding human pluripotent granulocyte colony-stimulating factor in a manner allowing expression of said polypeptide produce, and isolating desired polypeptide produce of the expression of said DNA sequence.

Details for Patent 4,999,291

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	February 20, 1991	4,999,291	2009-03-06
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	June 28, 2000	4,999,291	2009-03-06
Amgen Inc.	NEULASTA	pegfilgrastim	Injection	125031	January 31, 2002	4,999,291	2009-03-06
Amgen Inc.	NEULASTA ONPRO	pegfilgrastim	Injection	125031	December 23, 2014	4,999,291	2009-03-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 4,999,291

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
South Africa	866412	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	8701132	⤷ Get Started Free
United States of America	6716606	⤷ Get Started Free
United States of America	6379661	⤷ Get Started Free
United States of America	6004548	⤷ Get Started Free
United States of America	5830705	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.